Peptide Receptor Radionuclide Therapy with 177Lutethium or 90Yttrium- DOTA-TATE or –TOC in Malignant Pheochromocytomas (PCCs) and Paragangliomas (PGLs): Results from a single institutional retrospective analysis

#3478

Introduction: Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare tumors and limited systemic therapies are available so far.

Aim(s): To explore the role of peptide receptor radionuclide therapy (PRRT) with 90 Yttrium (90 Y) and 177 Lutethium (177Lu) in PGLs and PCCs.

Materials and methods: We retrospectively analysed patients with histologically proven advanced malignant PCCs and PGLs treated with 177Lu- or 90Y- DOTA-TATE or –TOC between 1999 to 2017 at our institution.

Conference:

Presenting Author: Rubino M

Authors: Rubino M, Di Stasio G, Spada F, Rocca P, Laffi A,

Keywords: Pheochromocytoma, Paraganglioma, Peptide Receptor Radionuclide Therapy, 90Y, 177Lu,